Company news

Imugene Ltd news in 2026

Imugene Ltd's news releases, calls and decks from 2026, newest first.

View company

Positive amendments to Convertible Notes

November 2, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Further Responses in azer-cel Phase 1b Trial

October 18, 2026

Further Responses in azer-cel Phase 1b Trial

October 18, 2026

Notification of cessation of securities - IMU

October 16, 2026

Application for quotation of securities - IMU

October 14, 2026

Application for quotation of securities - IMU

October 13, 2026

Notice of Annual General Meeting/Proxy Form

October 8, 2026

Dr John Le Gall appointed Chief Medical Officer

October 6, 2026

azer-cel BTKi Cohort Reports new Complete & Partial Response

October 4, 2026

Change of Director's Interest Notice - JD

October 1, 2026

Application for quotation of securities - IMU

September 8, 2026

Cleansing Notice

September 1, 2026

Application for quotation of securities - IMU

September 1, 2026

Change of Director's Interest Notice x4

September 1, 2026

Corporate Governance Statement and Appendix 4G

August 28, 2026

Appendix 4E and Annual Report

August 28, 2026

Notice under section 708A(12C)(e) of the Corporations Act

August 27, 2026

Notice of Initial Substantial Holding for IMU

August 27, 2026

Becoming a substantial holder for IMU

August 26, 2026

Notification regarding unquoted securities - IMU

August 26, 2026

Notification of cessation of securities - IMU

August 26, 2026

Application for quotation of securities - IMU

August 25, 2026

Amendment of Convertible Notes

August 20, 2026

Results of Extraordinary General Meeting

August 18, 2026

Letter To Shareholders

August 9, 2026

Expiry Of Listed Options

August 5, 2026

Final Director's Interest Notice - LC

July 31, 2026

Notification of cessation of securities - IMU

July 31, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

July 30, 2026

Third response in concurrent BTKi Cohort of azer-cel Trial

July 26, 2026

$11.1 Million Placement Completed to Advance azer-cel

July 6, 2026

New Complete Response in the Concurrent BTKi azer-cel Cohort

June 30, 2026

First Complete Response in Concurrent BTKi azer-cel Cohort

June 29, 2026

Azer-cel Granted FDA Fast Track Designation for CLL and MZL

June 8, 2026

First Patient in BTKi Combination Cohort of azer-cel study

May 27, 2026

Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract

May 21, 2026

Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)

May 20, 2026

Prospectus

March 17, 2026

$20M placement and SPP, convertible notes amended

March 11, 2026

100% and 80% ORRs in Subset Indications in azer-cel study

March 9, 2026

Trading Halt

March 9, 2026

Half Yearly Report and Accounts

February 25, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 29, 2026

Decks in 2026